Asset profile
enobosarm
Small molecule
Evidence outlook · lead readout
QUALITY (NCT06282458) · Muscle Loss, Obesity
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
QUALITY (NCT06282458): Participants were randomized and blinded to enobosarm dose or placebo while everyone received semaglutide. Adding enobosarm significantly reduced the amount of lean muscle mass lost during weight loss compared with placebo. Because the measure tested is a body-composition marker rather than a core disease outcome like body weight or physical function, this result reflects a real but more limited kind of evidence.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Enobosarm: this drug | Phase 3 | Small molecule | Androgen receptor (selective) | ||
| EP0062 | Phase 1/2 | Small molecule | Androgen receptor (selective) | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Orlistat (Xenical / Alli) | Approved | Small molecule | Pancreatic/gastric lipase | ||
| Phentermine / Topiramate (Qsymia) | Approved | Small molecule | Noradrenergic/anticonvulsant (combination) | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Setmelanotide (Imcivree) | Approved | Peptide | MC4R | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Apitegromab | Phase 3 | Monoclonal antibody | Activin/myostatin type II receptor | ||
| ARD-101 | Phase 3 | Small molecule | Bitter taste receptor (gut) | ||
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | ||
| AZD6234 | Phase 3 | Peptide | Amylin receptor |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
October 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.